Why Pharma Packaging Has Been Slow to Go Circular — and What’s Changing

The Unique Demands of Pharma Packaging

Pharmaceutical plastic packaging is, first and foremost, a product safety system. Bottles, blisters, dispensers, and closures protect medications from contamination, moisture, oxygen, and ultraviolet light, often over extended shelf lives and through complex global supply chains. Packaging is often produced in environments that meet standards like International Organization for Standardization (ISO) Class 7 and 8 for cleanroom environments. To meet compliance, consistent quality and reliable delivery are non-negotiable.

Pharmaceutical packaging formats run the gamut, from closures with tamper-evident seals to precision-dose dispensing systems. Each type of packaging is designed around the specific behavior of the drug it contains. That’s what makes reformulation so complex. Any change to a packaging material or structure typically requires regulatory submission and approval, a process that can take years and varies significantly across global markets.

To understand the challenge fully, look at the blister pack, which is one of the most common packaging formats for oral solid-dose medicines. Over the past 50 years, polyvinyl chloride (PVC) and aluminum have become the standard materials for blister packaging because of their barrier properties, compatibility, and manufacturability. From an environmental standpoint, PVC presents significant problems. As Healthcare Packaging reports, its lifecycle, from production through disposal, releases potentially concerning chemicals, and its composition makes it incompatible with most standard recycling streams. Even small amounts of PVC can contaminate other polymer recycling streams.

Multi-layer laminate structures that combine PVC, polyvinylidene chloride (PVDC), aluminum, and other materials for barrier performance are widespread in pharmaceutical packaging, and they’re similarly incompatible with mechanical recycling. As Packaging Gateway explains, when materials are permanently bonded this way, standard recycling processes can’t split them apart.

Contamination risk from drug residues is another concern. Producers need to demonstrate that new packaging materials don’t affect a product’s quality, safety, or efficacy, but the specific data requirements and submission pathways vary by market.

Regulation and ESG Pressure Are Creating a Deadline

Until recently, the barriers described above were sufficient to explain pharmaceutical packaging’s circularity lag. But things are finally changing.

The European Union's Packaging and Packaging Waste Regulation (PPWR), which entered into force in February 2025 and applies from August 2026, is accelerating the industry's transition toward more recyclable packaging through phased recyclability requirements and related obligations

Major pharmaceutical companies are publishing ESG commitments that include packaging sustainability targets, adding internal accountability alongside evolving regulatory requirements. Together, these forces are generating industry-wide momentum and driving innovation.

Top Trends in Pharmaceutical Packaging Circularity

A complex problem requires a multi-pronged approach. Pharmaceutical companies and packaging companies are exploring several distinct methods, each addressing a different aspect of the circularity challenge.

Reducing Excess Packaging

Lightweighting, or eliminating secondary packaging where it serves no protective function, and right-sizing formats for their actual contents can reduce material use without requiring regulatory submissions for primary packaging changes. This is where sustainability progress can begin now, while longer-term material transitions work through approval processes.

Reusable Packaging Formats

Reusables are more limited in pharmaceutical primary packaging due to sterility requirements. However, they’re gaining traction in specific pharmaceutical contexts, particularly for hospital and clinical supply chains where return logistics are already established. The Reusable Packaging Association points to rising adoption of reusable transport packaging across pharmaceutical and healthcare supply chains as evidence of this shift.

Mono-material Packaging

Perhaps the most significant trend in pharmaceutical packaging is the use of mono-materials. Take the work of the Pharmaceutical Manufacturing Forum (PMF) Working Group on Sustainable Blisters, for example. The group is made up of packaging leaders from leading pharmaceutical firms, and their goal is to address the transition from PVC-based blisters to alternatives.

Their findings, published in Healthcare Packaging, identify three mono-polymer formats with the most significant potential for widespread recyclability: polypropylene (PP), polyethylene (PE), and polyethylene terephthalate (PET). Mono-polymer blisters made from these materials can take advantage of established recycling streams in ways that PVC-aluminum composites can’t.

The working group’s findings also highlight that eliminating aluminum-based lidding foil in favor of plastic material can reduce carbon footprint by at least 50%, with further reductions available through smaller format design.

As Pharmaphorum reports, the shift to mono-material packaging also creates supply chain benefits beyond recyclability. Standardizing to a single material type simplifies procurement, reduces inventory complexity, and improves transportation efficiency. The pharmaceutical industry is seeing more frequent mono-material packaging collaborations, following patterns already established in food and beverage where the same transition is further advanced.

That same mono-material thinking is now reaching pump and dispenser mechanisms, the precision-dose dispensing systems mentioned earlier in this piece. Conventional dispenser pumps typically rely on a metal spring, which turns an otherwise-recyclable plastic pump into a mixed-material part that most recycling streams can't process. ALPLAhana, a joint venture between ALPLA and the South Korean pump specialist HANA Innovation, has developed a down-lock dispenser pump made entirely of polypropylene, replacing the metal spring with a durable plastic one instead. The result is fully recyclable, uses fewer components, and some of those components can be made from post-consumer recycled (PCR) material. The technology debuted in cosmetics packaging, but the underlying problem it solves, a metal spring hidden inside an otherwise mono-material plastic part, is common to pump-based dispensers across categories, including many used for liquid medications.

Recycling

Recyclability is only part of the picture. Without the right recovery infrastructure, recyclables just enter the waste stream. Existing frameworks like RecyClass in the European Union and the Association of Plastic Recyclers (APR) in the United States were designed for consumer goods, and adapting them to pharmaceutical formats requires direct industry engagement.

Johnson & Johnson has taken on that challenge. The company works with hundreds of hospitals across Europe, the Middle East, Africa, the United States, Australia, and New Zealand to recycle components from single-use medical devices and packaging. Its Safe Returns program allows patients to mail used home-administered devices back for disassembly and material recovery, with a dedicated disassembly facility operating in Switzerland for European collections.

The Industry That Solved the Unsolvable Is Turning Its Attention to Packaging

Pharmaceutical packaging has lagged behind other categories on circularity for legitimate reasons. Between regulatory barriers, material complexity, and safety requirements, every packaging decision comes with high stakes.

What makes the current moment encouraging is that the industry is bringing to packaging the same focused, coordinated problem-solving it has applied to far harder challenges. The pharmaceutical sector has a remarkable track record of treating problems that once seemed unsolvable. The same institutions, coalitions, and scientific resources that have produced some of the most complex medical breakthroughs in history are now focusing on the challenges like blister pack recyclability and take-back infrastructure. They’re supported by packaging companies like ALPLA, which have also committed to addressing these barriers.

While the pace may not be the same as other industries, the direction is clear.